The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Final results of BRIGHT AML 1003
Michael Heuser, MD, of Hannover Medical School, Hannover, Germany, discusses final 4-year overall survival results of BRIGHT AML 1003 (NCT01546038), a study investigating survival benefit of glasdegib plus low-dose cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
